Clostridium difficile infection across the United States Veterans Health Administration (original ) (raw )Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection
Chris Gentry
Journal of Clinical Pharmacy and Therapeutics, 2018
View PDFchevron_right
Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
Dale Gerding
Clinical Infectious Diseases, 2012
View PDFchevron_right
Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study
Chris Gentry
Clinical Microbiology and Infection, 2018
View PDFchevron_right
Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies
Dale Gerding
Open forum infectious diseases, 2014
View PDFchevron_right
Fidaxomicin Compared With Oral Vancomycin for the Treatment of Severe Clostridium difficile– Associated Diarrhea: A Retrospective Review
Kerry Cleveland
Hospital Pharmacy, 2019
View PDFchevron_right
Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
Arnold Lentnek
Clinical Infectious Diseases, 2012
View PDFchevron_right
Fluoroquinolone Use and Risk Factors for Clostridium difficile-Associated Disease within a Veterans Administration Health Care System
HENRY BENEDA
Clinical Infectious Diseases, 2007
View PDFchevron_right
Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection
Catalin I Plesea-Condratovici
JAMA internal medicine, 2017
View PDFchevron_right
Fidaxomicin for Clostridium difficile-Associated Diarrhoea
KURT BOWEN
Clinical Drug Investigation, 2012
View PDFchevron_right
The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
Travis Cole
Antibiotics, 2022
View PDFchevron_right
Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections
Arnold Lentnek
Clinical Infectious Diseases, 2011
View PDFchevron_right
Treatment of recurrent Clostridium difficile infection: a systematic review
Daniel Rodriguez
Infection, 2014
View PDFchevron_right
Safety and Efficacy of Fidaxomicin in Patients With Clostridium Difficile Infection
Christine Cocanour
Clinical Medicine Insights: Therapeutics, 2013
View PDFchevron_right
Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection
Manish Trivedi
Antimicrobial agents and chemotherapy, 2015
View PDFchevron_right
Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease
Christina Surawicz
The American journal of gastroenterology, 2002
View PDFchevron_right
Clostridium difficile infection: management strategies for a difficult disease
Sahil Khanna
Therapeutic Advances in Gastroenterology, 2013
View PDFchevron_right
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial
Benoit Guery
The Lancet. Infectious diseases, 2018
View PDFchevron_right
The management of Clostridioides difficile infection: from evidence to empirism
simona grad
Medicine and Pharmacy Reports
View PDFchevron_right
Predictors of First Recurrence of Clostridium difficile Infection: Implications for Initial Management
John Finney
Clinical Infectious Diseases, 2012
View PDFchevron_right
Prospective Observational Study Comparing Three Different Treatment Regimes in Patients with Clostridium difficile Infection
Daniela Schmid
Antimicrobial Agents and Chemotherapy, 2012
View PDFchevron_right
Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence
Konstantinos Vardakas
International Journal of Antimicrobial Agents, 2012
View PDFchevron_right
Increasing Incidence of Recurrent Clostridium Difficile Infection
FLORINA FILIP CIUBOTARU
2017
View PDFchevron_right
Overview of the Management Of Clostridium difficile
karla rivera
2014
View PDFchevron_right
Sustained Clinical Response as an Endpoint in Treatment Trials of Clostridium difficile-Associated Diarrhea
Dale Gerding
Antimicrobial Agents and Chemotherapy, 2012
View PDFchevron_right
Treating Clostridium difficile infection
S. Shafran
Canadian Medical Association Journal, 2014
View PDFchevron_right
Clostridium difficile Infection: New Insights Into Management
Sahil Khanna
Mayo Clinic Proceedings, 2012
View PDFchevron_right
Current clostridium difficile treatments: Lessons that need to be learned from the clinical trials
Ekaterini Christina Tampaki
Human Vaccines & Immunotherapeutics, 2018
View PDFchevron_right
A multi-center study of fidaxomicin use for Clostridium difficile infection
Radhika Polisetty
SpringerPlus, 2016
View PDFchevron_right
Clostridium difficile Infections: The Continuous Challenge
Mariam Kourani
2013
View PDFchevron_right
Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection
Charlesnika Evans
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015
View PDFchevron_right
Risk Factors for Relapse and Mortality of Clostridium Difficile- Associated Diarrhea
Pavlovic Momcilo
View PDFchevron_right
Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital
tatiana Galperine
Infection, 2017
View PDFchevron_right